BLOC1S6 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, featuring targeted disruption of the BLOC1S6 gene. This product provides a heterogeneous pool of gene-edited cells suitable for loss-of-function studies examining the biological roles of BLOC1S6 in a model intestinal epithelial background. The gene disruption is achieved through CRISPR/Cas9-mediated genome editing, resulting in a population of cells with varied knockout alleles that collectively abrogate BLOC1S6 function.
The HT29 cell line, originally established from a primary colorectal adenocarcinoma of a 44-year-old female, is a widely utilized model of intestinal epithelium. These cells retain the capacity to differentiate into enterocyte-like cells under appropriate culture conditions and are characterized by mucin production and formation of polarized monolayers. Consequently, HT29 cells are extensively employed in research on colorectal cancer biology, intestinal mucosal barrier function, drug absorption, and epithelial differentiation.
BLOC1S6 encodes a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), which mediates protein sorting from early endosomes to lysosome-related organelles. The BLOC-1 complex assembles through interactions among BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S6, DTNBP1, and SNAPIN, and functions downstream of mTORC1 signaling and the transcription factor TFEB. This complex facilitates the delivery of melanosomal enzymes such as TYRP1 and TYR, as well as components of platelet dense granules and lysosomal cargo. Its activity is critical for endosomal maturation and the biogenesis of diverse organelles including melanosomes and platelet dense granules.
In the HT29 colorectal cancer context, knockout of BLOC1S6 disrupts BLOC-1-dependent trafficking, likely impairing endosomal sorting and lysosome-related organelle function. This disruption may alter cellular processes such as proliferation, migration, and signal transduction, which are frequently dysregulated in cancer. Moreover, the model offers a unique system to explore the intersection of membrane trafficking defects with intestinal epithelial pathophysiology. It also provides a relevant cellular platform for modeling Hermansky-Pudlak syndrome type 7, a disorder linked to BLOC1S6 mutations, within an epithelial background.
Researchers can utilize this polyclonal knockout population for diverse applications, including western blotting and RT-qPCR to confirm gene disruption, immunofluorescence staining for lysosomal markers like LAMP1, and Lysotracker assays to assess organelle acidification. Functional studies such as transferrin uptake and recycling assays probe endosomal trafficking, while cell migration and proliferation assays evaluate cancer-relevant phenotypes. This model supports mechanistic dissection of BLOC-1 complex function in colorectal cancer and enables screening of compounds targeting membrane trafficking. For further details or custom cell engineering services, please contact Ascent Research.
